IRVING, TX--(Marketwire - February 01, 2008) - Novation, LLC, the health care industry’s leading contracting services company of VHA Inc. and the University HealthSystem Consortium (UHC), today announced that it is the first group purchasing organization (GPO) to have a national agreement with Medtronic for the Endeavor® Zotarolimus-Eluting Coronary Stent, the newest drug-eluting coronary stent on the U.S. market. On contract with Novation the day it received FDA approval, the Endeavor system represents a new generation platform for DES stents. It is the first U.S. commercially available DES built on a thin strut cobalt alloy platform -- the highly deliverable Driver® bare metal stent. This new platform offers improved deliverability and conformability in challenging anatomy. The contract is effective Feb. 1, 2008 - Sept. 30, 2010.
